The dasatinib is a substance that belongs to a new class of targeted anticancer drugs, so-called inhibitors of tumor growth. This class of molecules acts against tumors more selectively than traditional chemotherapy, as it recognizes some proteins that are on the wall of the tumor cells or within the cell; it blocks the mechanisms by which cells reproduce; since these proteins are only in a small part on healthy cells, it follows that the action is targeted towards cancer cells.
The inhibitors of tumor growth can kill tumor cells or only prevent the development.
The dasatinib is used in the treatment of chronic myeloid leukemia in patients who no longer respond to treatment with imatinib (Glivec ®) and in the treatment of adult patients with acute lymphoblastic leukemia with Philadelphia chromosome positive (Ph+).
Which is the principle of action?
The dasatinib is actually an inhibitor of protein kinase “BCR-ABL” enzyme, which is produced by leukemic cells and induces them to proliferate in an uncontrolled manner. The dasatinib is able to control the proliferation of leukemic cells by inhibiting, together, as a result, the kinases, in particular the BCR-ABL kinase.